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Abstract: The mechanisms responsible for the switch of prostate cancer from androgen-sensitive (AS) to androgen-insensitive (AI) form 
are not well understood. Regulation of androgen receptor (AR), through which androgens control the expression of genes involved in 
prostate cells proliferation, migration and death also involves its cross-talk with the other signaling pathways, transcription factors and 
coregulatory proteins, such as -catenin. With the aim to determine their possible contribution in triggering the switch from AS to AI 
form, which occurs upon androgen deprivation therapy - AR, Akt and -catenin expression were knocked-down with respective siRNAs. 
Treatment of LNCaP prostate cells with siRNA for AR significantly reduced their proliferation (45-70%), expression of nuclear -
catenin, cyclin-D1, cyclin-G1, c-Myc as well as activity of metalloproteinases (MMPs) -2,-7,-9 and cell migration. Surprisingly, after 
longer (over 72 hrs) silencing of AR in LNCaP cells, elevated levels of p-Akt were detected and enhanced proliferation as well as expres-
sion of nuclear -catenin, cyclin-D1, c-Myc and activity of MMPs were observed. Such effects were not observed in either PC-3 or 
DU145 AI cells. However, silencing of Akt and /or -catenin in those as well as in LNCaP cells led to their decreased proliferation and 
migration. Our findings suggest that in prostate cancer cells, either AR or Akt signaling prevails, depending on their initial androgen sen-
sitivity and its availability. In AI prostate cancer cells, Akt takes over the role of AR and more effectively contributes through the same 
signaling molecule, -catenin, to AI cancer progression. 
Keywords: Akt, androgen-insensitive, androgen-sensitive, androgen receptor, -catenin, metalloproteinases, prostate cancer, cyclin-D1,  
c-Myc, siRNA. 
1. INTRODUCTION 
Prostatic adenocarcinoma is one of the most frequently diag-
nosed malignancies and the second leading cause of cancer death 
amongst men in the developed world [1]. It has a high tendency to 
metastasize, making it very difficult to treat if not detected early. 
However, invasive or even micrometastatic disease presents a clini-
cal challenge, as these tumors respond poorly to standard cytotoxic 
regimens that act through genomic insult. Therefore, prostate can-
cer patients are often treated based on a unique characteristic of 
prostatic tissue, in that it is expressly dependent on androgen whose 
biological effects are mediated through the androgen receptor (AR), 
which regulates target gene transcription with respect to its develo-
pment, growth, and survival [2, 3]. Virtually all prostate cancer 
patients respond well when first treated with androgen ablation. 
However, resistance to hormonal blockade ultimately results in the 
recurrence of highly aggressive and metastatic prostate cancer that 
is androgen-independent.  
Tumoral development results from a multistep process that 
leads successively to the formation of low- and high-grade prostatic 
intraepithelial neoplasia, which is mainly under androgenic control 
[4]. Following androgen deprivation, the androgen dependence of 
prostate tissue is manifested by rapid cellular apoptosis, involution 
and progression to the regressed state [5]. As a result, androgen 
ablation induces initial tumor regression, but, after a limited time, 
the cancer relapses as an androgen-independent (AI) disease [6]. 
The mechanisms involved in the escape of prostate cancers from 
androgen control include mutation and over expression of the AR 
gene or ligand-independent activation by other signaling pathways 
[7]. In effect most, but not all, AI prostate cancer cells still express 
AR as well as the androgen-inducible prostate-specific antigen 
(PSA), suggesting that these cells maintain an active AR signaling 
pathway [8, 9]. Previous studies have demonstrated the value of 
using PSA immunohistochemistry in the diagnosis of metastatic 
prostate cancer [10]. However, recently it was shown that there 
 
*Address correspondence to this author at the Chair of Medical Biochemistry Jagiello-
nian University Medical College, ul. Kopenika 7, 31-034 Kraków, Poland;  
Tel:/Fax: +48124223272; E-mail: mblitewk@cyf-kr.edu.pl 
seemed to be no correlation between AR and PSA expression, 
strongly suggesting that the retained PSA expression may be driven 
by non-AR mediated mechanisms in late-stage prostate cancer [11]. 
In comparison to many types of cancer, prostate cancer takes 
longer to invade the adjacent tissues and spread to distant sites in 
the body. However, it is a life-threatening disease and no effective 
treatment is currently available. Therefore, it is important to under-
stand the molecular mechanisms behind the transition of prostate 
cancer from AS to AI state in order to search for new targets to treat 
advanced disease more efficiently. Some of the molecular players 
have been identified, but the process itself is far from clear.  
Our study describes a molecular mechanism very likely in-
volved in prostate cancer progression from AS to AI state. It in-
cludes the identification of a mechanism bypassing the principal 
role of AR in prostate cancer progression and has been supported 
by experimental studies presented in this report.  
It is well documented that the progression of many types of 
cancer is accompanied by or linked to increased expression of N-
cadherin. It seems to be a case for prostate cancer as well. The 
commonly studied AS prostate cancer cell line LNCaP express E-
cadherin but no N-cadherin at the mRNA and protein levels, while 
malignant AI prostate cell line PC-3 expresses no E-cadherin and 
shows unanimous presence of N-cadherin. The gain of N-cadherin 
expression in prostatic cells has been shown to be important in 
regulation of cell migration, invasion, proliferation and survival 
[12]. Jennbacken suggested that the expression of N-cadherin was 
influenced by androgen deprivation and was associated with metas-
tasis in prostate cancer [13]. They observed that expression of N-
cadherin increased in the absence of androgens in LNCaP-19 pri-
mary tumors and metastases and also in vitro, but not in PC-3 tu-
mors, indicating a possible involvement of the AR in the regulation 
of N-cadherin. Its expression was also associated with metastasis 
and Gleason score and was increased in castration-resistant tumors 
in patients with established metastases. This might indicate that 
castration induces molecular alterations in tumor cells, resulting in 
a more invasive and metastatic phenotype [13]. 
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As cadherins are crucial for regulation of -catenin, the possible 
effect of AR silencing on -catenin function was also investigated. 
-catenin, originally identified as a component of cell-cell adhesion 
structures, interacts with the cytoplasmic domain of E-cadherin and 
has a second function in the canonical Wnt (wingless/int) cascade 
that links E-cadherin to -catenin, which in turn mediates anchor-
age of the E-cadherin complex to the cortical actin cytoskeleton 
[14, 15]. 
The important kinase involved in modification and therefore the 
fate of –catenin is Akt. In PC-3 cells, a loss of adhesion and vi-
ability were associated with a loss of Akt phosphorylation at Ser473, 
which may explain the phenotype observed in PC-3 cells, critically 
dependent on PI3K signaling [16]. Assuming the roles of Akt and 
-catenin in prostate cancer, we decided to knock out them selec-
tively or together in AS and AI prostate cancer cells with the aim to 
elucidate the mechanism that might be responsible for the switch of 
prostate cancer from androgen-sensitive to androgen-insensitive. 
Our findings suggest that in prostate cancer cells either AR or Akt 
signaling prevails depending on androgen sensitivity and availabil-
ity. We demonstrate that in AS prostate cancer cells, AR signaling 
recruits -catenin through which it affects the expression of crucial 
mediators of cell behavior. It seems that in AI prostate cancer cells, 
Akt takes over the role of AR and signals through the same signal-
ing molecule, -catenin, resulting in highly invasive androgen inde-
pendent cancer progression. 
2. MATERIALS AND METHODS 
2.1. Cell Lines 
The following established cell lines or primary cells were used: 
LNCaP - androgen-sensitive, brain metastasis; and PC-3, androgen-
insensitive, lymph nodes metastasis, and DU145 – androgen-
insensitive, metastatic prostate carcinoma from brain metastasis, 
human prostate cancer cell lines (American Type Culture Collec-
tion, Manassas, Virginia, USA), CA-K - primary prostate cancer 
cells and BPH-K – primary benign prostate hyperplasia cells de-
rived as described previously [9]. Treated and untreated cells were 
maintained in RPMI-1640 medium (Sigma, Poland) supplemented 
with 10% fetal bovine serum and 100 U/ml penicillin and 100 
μg/ml streptomycin. When steroid hormone (dihydrotestosterone, 
testosterone) was added to medium charcoal-stripped fetal calf 
serum (SF - steroid free) was used. In some cases, the cells were 
treated with testosterone or dihydrotestosterone (Sigma; 1-10nM) 
for 1 to 5 days. 
2.2.Tissue Samples and Isolation of Cells 
Tissue samples - 20 prostate cancer, 15 hyperplasic and 7 nor-
mal were collected at the time of surgery from the Department of 
Surgery Military Hospital, Krakow (consent of Bioethics Commit-
tee n° KBET/36/B/2010). Among prostate cancer samples there 
were 8 well-differentiated (Gleason score 2-4), 9 moderately differ-
entiated (Gleason score 5-7) and 3 poorly differentiated adenocar-
cinomas (Gleason score 8-10). All prostate tissue samples used in 
the study were histopathologically confirmed (Department of Pa-
thology, Jagiellonian University Medical College, Krakow, Po-
land). The median age of patients with prostate cancer was 68.5 
years (range 38-84). The preparation of tissue slices and the isola-
tion of cells from them was performed as previously described [17, 
18]. Cells were released by overnight treatment of tissue slices in 
0.125% trypsin solution [9].  
2.3. siRNA Transfection 
Prostate cells were grown until 60% confluence and then trans-
fected using Lipofectamine-2000 according to the manufacturer’s 
protocol with three different 21bp double-stranded siRNA mole-
cules specifically targeting the AR- ID# 289124, ID# 146896, ID# 
4096; Akt - ID# 103719, ID# 103718, ID# 118270; -catenin - 
ID#146154, ID#146156, ID#146155 or a control non-silencing 
sequence (Ambion, Life Technologies, Poland). All cells were 
transfected with 80 nM siRNA. After 24 h, the medium was re-
placed with fresh medium and cells were grown for an additional 
48h period (72h post-transfection, 96h or 120h) prior to isolation of 
RNA and protein for further analysis.  
2.4. Cytotoxicity of siRNA 
The cells were seeded in triplicate into 96-microwell plates at a 
density of 1.5 x 103 cells/well and incubated with or without the 
specific siRNA (AR, Akt, -catenin) for 48, 72, 96 or 120h. Nega-
tive and positive controls were also included. Colorimetric assays 
were performed according to manufacturer’s instructions (Cytotox-
icity Detection Kit, Roche Diagnostics, Poland) and as described 
elsewhere [18]. Absorbance of the colored product - formazane - 
was measured at 492 nm by an ELISA reader (Synergy HT, BIO-
TEK, USA). No cytotoxic effects of the used concentrations of 
siRNAs on any of the studied cell lines were observed.  
2.5. Cell Proliferation (ELISA, BrdU) 
Cells were seeded in triplicates into 96-microwell plates at a 
density of 1.5 x 103 cells/well and cultured in medium with or with-
out the different siRNAs for AR, Akt and -catenin in the presence 
of positive and negative controls for various periods of time (24-
120h). ELISA BrdU (Roche) colorimetric immunoassay tests were 
performed as described previously [18]. The absorbance was meas-
ured at 450 nm on an ELISA plate reader.  
2.6. Cell Migration and Invasion Assay 
Cell migration and invasion assays were performed using con-
ventional Boyden transwell methods according to the manufac-
turer’s protocol (BD BioCoat Tumor Invasion System No. 354166, 
Poland). Quantitation of invasive cells was achieved by post inva-
sion cell labeling with calcein and measuring the fluorescence of 
invading cells. 
2.7. Zymography 
Gelatinolytic activities of metalloproteinases MMP-2 and 
MMP-9 were evaluated from the conditioned medium. Proteins 
were separated on 10% polyacrylamide gels containing 0.1% gela-
tin (Sigma, Poland) under nonreducing conditions. After electro-
phoresis, the gel was washed two times for 30 min in 2.5% Tri-
tonX-100. After 48 h incubation at 37°C in buffer (50 mM Tris pH 
7.5; 10 mM CaCl2; 0.15 mM NaCl) the gel was stained with 1% 
Coomasie blue R250 for 1h and its excess was eluted with methanol 
(50%)/acetic acid (10%) solvent. Gelatinolytic activity was ob-
served as clear areas in the gel. 
2.8. Preparation of Nuclear and Cytoplasmic Cell Lysates 
Nuclear and cytoplasmic extracts were prepared using the Cell-
Lytic NuCLEAR Extraction Kit (Sigma, Poland) according to pro-
ducer’s protocol and equal amounts of protein were used in im-
munoblot analysis. 
2.9. Western Blot Analysis 
Cells were lysed in sample buffer (0.0625 M Tris/HCl pH 6.8, 
2% SDS, 10% glycerol, 5% -mercaptoethanol). Cell lysates con-
taining equal amounts of protein were separated on 10% SDS-
PAGE gels, and subsequently transferred onto a PVDF membrane. 
Antibodies against: Akt, phospho-Akt(S473), AR, -catenin, phos-
pho- -catenin(S552), c-Myc, cyclin D1, E-, N-cadherin, p21, p27 
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(all Lab-JOT - Cell Signaling Technology, Poland), -actin (Sigma, 
Poland), PSA (DAKO, Denmarck) and MMP-2, -7, -9 (Santa Cruz, 
USA ) were used to detect indicated proteins. Total protein loading 
was determined by probing the membranes for -actin. Bands were 
visualized using alkaline phosphate-coupled secondary anti-mouse 
or anti-rabbit antibody (Sigma, Poland). Finally, immunoreactions 
were visualized by NBT/BCIP staining (Roche, Poland).  
2.10. RNA Extraction, cDNA Synthesis and RT-PCR Analysis 
RNA extraction, preparation of cDNA and RT-PCR reaction 
were carried out as previously described [19]. The temperature 
profile of RT-PCR amplification consisted of activation of Taq 
polymerase at 95° C for 4 min, denaturation of cDNA at 95°C for 
30–45 s, applying primer annealing temperature for 30–40 s, elon-
gation at 72°C for 40–60 s for the following 35 cycles and comple-
tion of the process by the extension step for 10 min. PCR protocols 
were optimized for each studied gene according to the specific an-
nealing temperature (Table 1). The PCR reaction products were 
separated electrophoretically on 2% agarose gel and visualized with 
ethidium bromide. 
2.11. Real-Time PCR 
In parallel, cDNA was synthesized using 1000 ng of aliquots of 
total RNA primed with Superscript II reverse transcriptase (Invitro-
gen, Poland) and oligo d(T) primers (Sigma) in 20 μl reactions vol-
ume in a thermocycler DYAD (MJ Research, Inc., Waltham, MA. 
USA) After reverse transcription, cDNA was dissolved in water 
(2:3) Next, 5μl of cDNA solution was added to the RQ-PCR reac-
tion. Specificity was determined by BLAST searches. Real-time 
PCR (RQ-PCR) was performed using the 7500 Real-Time PCR 
System (Applied Biosystems, foster City, USA) and TaqMan 
probes. Specific primers and probes for MMP9 gene and the ABL 
control gene were purchased from TIB MOLBIOL (Pozna , Po-
land) and Applied Biosystems (Applied Biosystems, Cheshire, 
UK), respectively: ABL - forward primer ENF1003 5’TGGAGA-
TAA CACTCTAAGCATAACTAAAGGT3’, reverse primer 
ENR1063 5’GATGTAGTTCTTGGG ACCCA3’, molecular probe 
ENP1043 Fam - CCATTTTTGGTTTGGGCTTCACACCATT-
Tamra; MMP9 - (forward, 5’AATCTCTTCTAGAGACTG GGAA 
GGAG3’; reverse, 5’AGCTGATTGACTAAAGT AGCTG GA3’. 
The standardized protocol for the comparative threshold cycle (Ct) 
cycle (Ct) method was used as described in the Europe Against 
Cancer program. Amplification was performed using recommended 
standard conditions [20]. RQ-PCR results were expressed using the 
CT method and relative RNA expression was calculated according 
to Macabeo-Ong et al. [21]. All experiments were performed in 
triplicate, and mean values were calculated. Negative controls lack-
ing template RNA were always included in each experiment. 
2.12. The Limitations of the Study 
In order to demonstrate differences in expression of the investi-
gated genes, the authors used research material originating from 
prostate tissue biopsy specimens (normal and cancer tissues with 
various tumor stages – Gleason score). In view of the limited 
amount of material with a normal phenotype only 7 tissues was 
employed in the investigations. 
2. 12. Statistical Analysis 
All data of the proliferation and cytotoxicity experiments repre-
sent the average of five wells in each experiment (n=4). Data was 
expressed as mean ± standard deviation. In cases of RT-PCR and 
western blotting, each analysis was performed in triplicate. The 
significance of the differences between mean values were calcu-
lated using Student's t Test (  = 0.05). 
3. RESULTS 
To assess the actual changes in expression of AR, Akt, -
catenin, E- and N- cadherins, cyclin-D1, c-Myc, as well as activity 
of MMPs and cell cycle inhibitors p21Cip-1 and p27Kip-1, we used 
established prostate cancer cell lines: LNCaP (androgen-sensitive 
AS), PC-3 and DU145 (both androgen-insensitive AI), as well as 
primary cells derived from tissue specimens, one prostate cancer 
(CA-K) and one benign prostate hyperplasia line (BPH-K) [9] and 
respective tissues of their origin. Elevated expression of PSA, -
catenin, cyclin-D1 and c-Myc and decreased or lack of expression 
of E-cadherin was observed in AI cells and in cancer tissues Fig. 
(1). Expression of AR also depended on the stage of tumor, but 
there was no typical correlation between the degree of malignancy 
and expression of AR (data not shown). However, the observed 
alternations in expression of AR confirmed the lack of an obvious 
direct relationship between the kind of tissue/cell (normal, hyper-
Table 1. Primers Used for RT-PCR Analysis 
 
Primer Protein Sequences Conditions 
GAPDH 5’CACCGCCTCGGCTTGTCACAT 3’; 5’CTGCTGTCTTGGGTGCATTGC3’; 59°C, 30 s 
PSA 5’TTGTCTTCCTCACCCTGTCC3’; 5’TGTCCTTGATCCACTTCCGGTA3’ 59°C, 40 s 
AR 5’TGTCAACTCCAGGATGCTCTACTT3’; 5’ATTCGGACACCACTGGCTGTACA 3’ 55°C, 45 s 
N-CADHERIN 5’GTGCCATTAGCCAAGGGAATTCAGC3’; 5’CGAGGATACTCACCTTGTCCTTGCG 3’ 68°C, 40 s 
E-CADHERIN 5’ GCCAAGCAGCAGTACATTCTACACG3’; 5’ GTCGTTCTTCACGTGCTCAAAATCC 3’; 68°C, 40 s 
-CATENIN 5’-GCTGATTTGATGGAGTTGGA3’; 5’TTCACTCAAGAACAAGTAGC3’ 55°C, 120 s 
CYCLIN D1 5’TGTTCGTGGCCTCTAAGATGA3’; 5’GCTTGACTCCAGAAGGGCTT3’ 60°C, 60 s 
C-MYC 5’CAAGAGGCGAACACACAACGTCT3’; 5’AACTGTTCTCGTCGTTTCCGCAA3’ 55°C, 60 s 
MMP2 5’ GTGCTGAAGGACACACTAAAGAAGA3’; 5’TTGCCATCCTTCTCAAAGTTGTAGG3’ 59°C, 60 s 
MMP9 5’AGATTTCGACTCTCCACGCA - 3’; 5’CTGAGAACCAATCTCACCGACA - 3’ 60°C, 60 s 
MMP7 5’TCGATGAGGATGAACGCTGGACGG3’; 5’TGCTAAATGGAGTGGAGGAACAGTGC3’ 60°C, 60 s 
Androgen Receptor Inactivation and Akt Expression Current Medicinal Chemistry, 2013, Vol. 20, No. 1      147 
plasic, cancer stage) and the level of this receptor additionally re-
flecting the variation in its mRNA/protein stability [Fig. (1). A and 
B lane AR]. The observed different expression of selected proteins 
in various cell lines and tissues indicated phenotype alterations due 
to cancer progression. The cell lines PC-3, CA-K and cancer tissue 
CA did not express E-cadherin, while we noted there was expres-
sion of N-cadherin both at mRNA and protein level in these sam-
ples. Additionally, in the same cells and respective tissues samples, 
expression of -catenin, cyclin D1 and c-Myc showed similar in-
creasing trends. Expression of AR in AI cells was not observed Fig. 
(1). 
We previously reported on the differential response of prostate 
cells to treatment with peroxisome proliferator-activated receptor 
gamma (PPAR ) ligands (fatty acids, ciglitazone) or kinetin ri-
boside in respect to their androgen sensitivity [9, 18, 22]. We were 
also able to show the strong effect of T and DHT on the expression 
of genes/proteins related to proliferation and apoptosis in AS hu-
man prostate carcinoma cells. Therefore, we sought to determine 
whether cell behavior could be modulated in response to silencing 
AR activity.  
Cells were treated with DHT or T under previously described 
conditions [18]. AS LNCaP cells stimulated with T or DHT showed 
elevated proliferation Fig. (2A) and high levels of nuclear -catenin 
and AR Fig. (2B) as well as migration Fig. (2C-D). No such effects 
were observed with AI DU145 and PC-3 cells. Interestingly, in 
LNCaP cells, increased -catenin levels in nucleus were accompa-
nied by increased levels of AR Fig. (2B). The observations on the 
interactions between -catenin and AR suggest a possible mecha-
nism of the cross talk between -catenin and AR signaling path-
ways [23]. It also seems that DHT has a stronger impact on AR-
mediated proliferation and the transport of -catenin to nucleus as 
compared to testosterone [Fig. (2A) and data not shown]. There-
fore, DHT was used in further studies as the AR ligand when its 
effects on AR-mediated proliferation and migration were investi-
gated. DHT significantly influenced the migration and MMPs activ-
ity in LNCaP cell line Fig. (2). 
Because MMPs are involved in tumor metastasis, we compared 
the constitutive levels of MMP gene expression in prostate cancer 
cell lines with different metastatic potentials Fig. (2C). A signifi-
cantly higher level of MMP-9 gene expression was observed in PC-
3 and DU145 cells compared with LNCaP cells. MMP-9 activity in 
LNCaP cell line increased after treatment with DHT Fig. (2C). 
Treatment of LNCaP prostate cells with siRNA for AR signifi-
cantly reduced proliferation (45-70%), expression of cell cycle 
proteins - cyclin D1 and cyclin G1, c-Myc, cell migration and activ-
ity of MMPs after 72hrs Fig. (3A-E). We observed that LNCaP 
cells transfected with siRNA specific for AR completely lost the 
ability to migrate through Matrigel-coated Boyden chambers when 
compared with respective control cells Fig. (3B). In parallel, in-
creased expression of E-cadherin, p21Cip-1 and p27Kip-1 in LNCaP 
cells were observed Fig. (3D). In contrast, neither proliferation nor 
migration were affected by PC-3 and DU145 cells after transfection 
with siRNA specific for AR. 
mRNA and protein analysis revealed that LNCaP cells ex-
pressed E-cadherin but not N-cadherin Fig. (1). The gain of N-
cadherin expression in prostate has been shown to be important 
with respect to regulation of cell migration, invasion, proliferation 
and survival [19]. AR knockdown led to increased expression of E-
cadherin in LNCaP cells. A similar observation was recently made 
in BPH-K primary cells [9]. As cadherins are crucial for regulation 
of -catenin, the possible effect of AR silencing on -catenin func-
tion was investigated. The results confirmed the participation of AR
 
 
Fig. (1). Expression of E-, N-cadherin, -catenin, cyclinD1, c-Myc and AR in various human prostate cells and tissues at mRNA (Panel A) and protein (Panel 
B) levels. RT-PCR analysis. The cells and tissues examined were: LNCaP (AS), PC-3 and Du145 (AI), BPH-K (primary benign prostate hyperplasia cells), 
CA-K (primary prostate cancer cells) derived as described previously [16] and their respective BPH and CA, as well as, normal prostate tissues. The upper 
lanes show the levels house-keeping genes GAPDH or -actin under the same culture conditions. 
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Fig. (2). The effect of androgen [1nM dihydrotestosterone (DHT) or 1nM testosterone (T) treatment of LNCaP, PC-3 and DU145 prostate cancer cells on: 
Panel A. proliferation, the graph insert in the right upper quadrant shows the proliferation of cells over time; Panel B. Total cell protein extracts were analyzed 
for AR by western blot analysis. -catenin cytoplasmic and nuclear expression was examined by western blot analysis. Cytoplasm and nuclear protein extracts 
were prepared as described in M&M. Panel C. Zymography - Gelatinolytic activities of MMP-2 and MMP-9. Panel D. cell invasion assay through Matrigel 
coated Boyden chamber. Table presents quantification of cell invasion which are presented as the mean +/- SD from three independent experiments. 
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Fig. (3). The effects of AR knock-down in LNCaP, PC-3 and DU145 prostate cancer cells were determined by various approaches. In panel A, cell prolifera-
tion was measured over a 24-120hrs time period. In panel B, cell invasion assays through Matrigel coated Boyden chamber are presented in a table which quan-
tifies the extent cell invasion. In Panel C. MMPs expression was examined at the mRNA level in LNCaP cells. In Panel D, the expression of: MMP7 and 
MMP2, cyclin D1, cyclin G1, c-Myc and E-cadherin, p21Cip-1 and p27Kip-1 in the LNCaP cell line were examined at the protein level. In panel E, -catenin ex-
pression and its nuclear translocation was determined. Total cell lysates as well as cytoplasmic and nuclear fractions were analyzed for -catenin expression by 
western blotting. Representative results of at least four independent experiments are presented. 
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in the translocation of -catenin, as DHT treatment increased the 
nuclear levels of -catenin while silencing of AR led to decreased 
levels of nuclear localized -catenin Fig. (3E). As might have been 
expected, we did not detect a significant difference between control 
and AR siRNA transfected cells, with respect to -catenin localiza-
tion, in the case of the AI DU145 and PC-3 cells Fig. (3E). Surpris-
ingly, after AR silencing for a period longer than 96 hrs in LNCaP 
cells, we observed increased levels of proliferation Fig. (3A) as 
well as elevation of p-Akt levels and MMPs activity Fig. (4). These 
effects were not observed in either PC-3 or DU145 cells Fig. (4A). 
Additionally we observed changes in the levels of -catenin phos-
phorylation at Ser 552 after longer periods (120h) of AR silencing 
in LNCaP cells. Significantly higher levels of -catenin phosphory-
lation after 120 hrs of AR knock-down were detected in these cells. 
In addition, we noted significantly increased migration of LNCaP 
cells treated for 120h with AR siRNA through Matrigel-coated 
Boyden chambers compared to untreated cells Fig. (4B). 
To confirm the presumed role of Akt in prostate cancer progres-
sion as the main mediator of -catenin function in AR knocked-
down cells, Akt expression was also silenced. In this case, the im-
portant effects of Akt knock-down were observed in PC-3 and 
DU145 cells, as siRNA specific for Akt caused inhibition of prolif-
eration (50-60%) in AI cell line and surprisingly only 10-20% in 
AS LNCaP cells line Fig. (5A). Silencing of Akt gene caused inhi-
bition of both of Akt and -catenin expression in AI PC-3 and 
DU145 cells. In contrast, Akt silencing in AS LNCaP cells did not 
result in a change in -catenin expression Fig. (5B). Treatment of 
Akt-depleted LNCaP cells with DHT led to an increase of prolifera-
tion and -catenin expression as well as its translocation to the nu-
cleus. The results indicated that translocation of -catenin to the 
nucleus depended more on AR than Akt activity in AS cells. In 
contrast, translocation of -catenin to the nucleus in AI cells de-
pended mainly on Akt activity Fig. (5).  
Our results indicated that proliferation in prostate cancer cell 
lines depends both on AR and Akt regulation. To confirm these 
results, we knocked-down AR and Akt simultaneously. Simultane-
ous silencing of AR and Akt resulted in 70-85% inhibition of pro-
liferation in AS LNCaP cells, whereas simultaneous silencing of 
AR and Akt resulted in 50-70% and 55-60% in PC-3 and DU145 
inhibition of proliferation in the AI cell lines, respectively Fig. 
(6A). Silencing of both AR and Akt genes caused a higher degree 
of inhibition of Akt expression and -catenin nuclear levels in AS 
as compared to AI cells PC-3 and DU145. In addition, decreased 
expression of cyclin D1 and increased levels of p21Cip-1 were ob-
served Fig. (6). These results indicated that both AR and Akt regu-
late prostate cancer and one of their main targets is -catenin. 
Therefore, to confirm that both AR and Akt use -catenin as an 
important factor involved in the regulation of gene transcription, we 
also silenced -catenin. -catenin knock-down caused significant 
inhibition of proliferation Fig. (7A) in prostate cell lines and was 
sufficient to down-regulate the expression of cyclin D1, c-Myc and 
to increase p21Cip-1 expression, but the most potent effects were 
observed in LNCaP cells Fig. (7B). Similar decreases in the expres-
sion of MMPs and the migration of cells were observed in all lines 
when either siRNA for AR+ siRNA for Akt or siRNA for -catenin 
were used Fig. (8A, B). 
4. DISCUSSION 
The Role of the Androgens and AR Expression in Prostate 
Cancer Progression 
The regulation of gene expression by steroid hormones, in par-
ticular androgens, plays an important role in the development of 
normal prostate and strongly influences the pathogenesis of steroid 
dependent prostate cancers. In the process of tumor progression, 
fundamental changes in the expression of proteins involved in cell 
signaling are observed. Only a small number of studies have at-
tempted to explain the mechanism of prostate cancer with respect to 
the regulation of cell signaling pathways and their cross-talk on AR 
activity. 
In order to understand prostate cancer progression and possibly 
to treat it more successfully, one of the most important questions 
addresses the development of its AI phase. Among human patients, 
androgen deprivation therapy is usually performed by administra-
tion of gonadotropin-releasing hormone analogs and/or surgical 
castration (orchiectomy), often in combination with anti-androgens, 
such as flutamide or bicalutamide to treat AS prostate cancer. 
Probably due to selective pressure, AI prostate cells have the capa-
bility to escape from the effect of castration and antiandrogens; 
exclusion of the AR activity by inhibition of dimerization or inhibi-
tion of DNA binding seems to be the next step [24]. Prostate cancer 
growth is stimulated initially by circulating testicular androgens 
[25]. Even when prostate cancer progresses to the castration resis-
tant phase, AR activation and signaling remains sustained through a 
variety of mechanisms [26, 27]. Mechanisms for increased AR 
transactivation during prostate cancer progression to castration-
resistant growth include AR gene amplification [28], somatic AR 
gene mutations that provide a gain of function by decreasing AR 
ligand specificity and increased AR interactions with coregulators, 
whose levels also increase during prostate cancer progression [29]. 
Prostate cancer tissue production of androgen develops during an-
drogen deprivation therapy [30, 31] and increased mitogen signal-
ing as well as AR phosphorylation influences AR transcriptional 
activity [32]. Mohler et al. [33], reported that the extent of AR 
transactivation in the presence of 5 -androstane-3 ,17 -diol (an-
drostanediol) in prostate-derived cell lines parallels the bioconver-
sion of androstanediol to DHT. We were able to show that DHT 
increased proliferation in LNCaP prostate cancer AS cell line and 
the levels of AR and -catenin expression. The results obtained 
confirm the participation of AR in the translocation of -catenin, as 
liganded AR increased the nuclear level of -catenin rather than 
inhibition as in the case of AR silencing. Other findings demon-
strate that AR can regulate -catenin signaling, that the AR- -
catenin interaction can enhance -catenin/Tcf4 signaling and con-
tribute to aggressive biological behavior of prostate cancer [34]. We 
observed that the -catenin levels in the nucleus were higher when 
the levels of AR increased. Also Verras suggested a possible 
mechanism of cross talk between -catenin and androgen signaling 
pathways [23, 35]. It seems that AR liganded by DHT has a more 
potent impact on the transport of -catenin to the nucleus than AR 
liganded by testosterone. The subsequent observations indicated 
that DHT significantly influences the migration and MMPs activity 
in LNCaP cell line. Similar effects, namely enhanced cell migra-
tion, were observed after exposure of LNCAP T RII cells to DHT 
[36].  
Silencing of AR 
We determined that treatment of LNCaP prostate cells with 
siRNA specific for AR significantly reduced: proliferation, expres-
sion of cell cycle proteins cyclin-D1, cyclin G1, c-Myc, cell migra-
tion and activity of MMPs. Furthermore, we observed that LNCaP 
cells transfected with siRNA specific for AR showed almost com-
pletely reduction of their migration ability. In contrast, similar 
transfection of siRNA specific for AR only reduced 15% of the 
ability of DU145 cells to migrate through Matrigel-coated Boyden 
chambers, while there were no changes in case of PC-3 cells. On 
the other hand, increased expression of E-cadherin, cell cycle in-
hibitors p21Cip-1 and p27Kip-1 were observed. Silencing of AR inhib-
ited the nuclear translocation of -catenin only in the AS LNCaP 
cell line. The inhibition of -catenin nuclear translocation persisted 
for 72 hrs. A common feature shared by genes including: MMP-2, 
c-Myc, cyclin D1, IGFBP6, IGF-1R, IGF2 and PI3K [37] is that
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Fig. (4). The effects of prolonged AR silencing in LNCaP, PC-3 and DU145 prostate cancer cells on gene expression and migration. Panel A). -catenin and 
p -catenin(pSer552) expression and their cellular localization. Also the levels total Akt and pAkt in the same lysates are presented. Panel B). migration through 
Matrigel coated Boyden chamber and activities of MMP-2 and MMP-9 (LNCaP cell line). Prostate cells were transfected with control siRNAs or three different 
21 bp double-stranded siRNA targeting the AR. 72h and 120h after transfection, protein expression was analyzed by Western blot. Total protein loading was 
determined by probing the membranes for -actin. Representative results of at least four independent experiments are presented. 
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Fig. (5). Effects of Akt silencing in LNCaP, PC-3 and DU145 prostate cancer cells. Panel A). proliferation. Panel B). AR and nuclear -catenin expression. 
Prostate cells were transfected with control siRNAs or three different 21 bp double-stranded siRNAs targeting the Akt. 72h after transfection, protein expres-
sion was analyzed by western blotting. Total protein loading was determined by probing the membranes for -actin. Representative results of at least four inde-
pendent experiments are presented. 
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Fig. (6). Effects of co-targeting AR and Akt in LNCaP, PC-3 and DU145 prostate cancer cell lines. Panel A). Proliferation after 24-120hrs of treatment. Panel 
B). AR, Akt, cyclin D1, p21Cip-1 and -catenin expression. Prostate cells were transfected with control siRNAs or three different 21 bp double-stranded siRNAs 
targeting the AR and Akt. 72h and 120h after transfection, protein expression was analyzed by western blotting. Total protein loading was determined by prob-
ing the membranes for -actin. Representative results of at least four independent experiments are presented. 
 
they are directly or indirectly associated with the -catenin-
signaling pathway [35]. Activation of the -catenin pathway has 
been observed in prostate cancer patients. A recent study showed 
that 32% of patients with advanced disease carried mutations in the 
-catenin gene [38]. Oncogenic activation of the -catenin-
signaling pathway has been reported to result in the abnormal ac-
cumulation of -catenin. The translocation of -catenin-TCF-4 
complex to the nucleus leads to transcriptional activation of target 
genes, such as c-Myc, MMP-2 and cyclin D1 [39, 40]. To deter-
mine the effects of AR silencing on proliferation, Akt activation 
and the expression of -catenin-regulated genes in prostate cancer 
cells that are normally AS, we silenced AR in LNCaP cells for pe-
riods longer than 72hrs. To our surprise, we observed increased 
proliferation, increased cyclin D1, and c-Myc expression, increased 
MMP activity, elevation of p-Akt levels as well as p- -catenin 
(pSer 552). The higher expression of p-Akt and p- -catenin may
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Fig. (7). The effects of -catenin silencing in LNCaP, PC-3 and DU145 prostate cancer cell lines. Panel A). Proliferation, Panel B). Protein expression - -
catenin, c-Myc, cyclin D1, p21Cip-1. Prostate cells were transfected with control siRNAs or three different 21 bp double-stranded siRNAs targeting -catenin. 
72h and 120h after transfection, protein expression was analyzed by western blotting. Total protein loading was determined by probing the membranes for -
actin. Representative results of at least five independent experiments are presented. 
 
suggest the participation of Akt- -catenin in the regulation of pro-
gression of prostate cancer in the case of acquired AI, which seems 
to be confirmed by their increased migration.  
Akt Knock-Down 
The effects of Akt knock-down on these biological processes 
were observed in AI PC-3 and DU145 cells and not in AS LNCaP 
cells. siRNA specific for Akt caused over 50% inhibition of prolif-
eration in AI cells, but only 10-20% in AS cell line. Silencing of 
Akt gene caused inhibition both of Akt and -catenin expression in 
AI cell lines PC-3 and DU145, without a significant change in -
catenin expression in AS LNCaP cell line. The exact mechanism by 
which the phosphorylation of -catenin at Ser552 positively regu-
lates the expression of its target genes remains unclear. One possi-
bility exists that phosphorylation of Ser552 may modulate the trans-
location of -catenin through nuclear pores, while a second possi-
bility is that phosphorylation by Akt occurs within the nucleus and 
affects function rather than localization [41]. Further studies are 
needed to determine whether the phosphorylation of -catenin at 
Ser552 exerts the same effect as stabilized -catenin on binding to 
the Tcf4/Lef1 complex and activating the transcription of Wnt tar-
get genes.  
Function of -Catenin in Cancer Progression 
Up-regulation of -catenin is a common feature of tumorigene-
sis that can be affected through mutations in -catenin genes or 
other genes functioning in this pathway. Such genetic defects that 
result in up-regulation and stabilization of -catenin play an impor-
tant role in melanoma progression [42]. On the contrary, Fang et al. 
[43] showed that -catenin accumulation in the nucleus is not suffi-
cient for -catenin/TCF transcriptional activity. They observed that 
cells stably transfected with -catenin S552A had reduced tran-
scriptional activity that has been closely related to tumor cell inva-
siveness. Daugherty and Gottardi [43] and Fang et al. [44] reported 
that phosphorylation of -catenin at C-terminal residues Ser 552 by 
Akt was necessary for the promotion of -catenin-regulated tran-
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scriptional activity. In addition, Miyabayashi et al. [45] suggested 
that the particular co-activators recruited to -catenin may dictate 
which target genes are activated and that this differential recruit-
ment can be regulated by phosphorylation. Gil et al. [46] also sug-
gested the central role of phosphorylation in the regulation of -
catenin signaling, since phosphorylation of -catenin at Ser 552 is 
completely abolished upon ILK silencing in melanoma cell lines, 
also in the nuclear fraction from 1205Lu metastatic cell lines. Caspi 
et al. [47] and Gardner et al. [48] discovered GSK-3 -dependent 
and independent mechanisms that regulate -catenin activity. 
Gardner et al. [48] suggested that the phospho-inhibition of GSK-
3  at Ser 9 is not necessary for -catenin/TCF signaling. In addi-
tion, Caspi et al. [47] using colorectal cell lines that express a mu-
tant form of -catenin, which cannot be phosphorylated by GSK-3  
and ectopically expressed mutant -catenin, demonstrated that nu-
clear GSK-3  functioned in a mechanism that did not involve -
catenin phosphorylation. Our results indicated that translocation of 
-catenin to nucleus in AS cells was to a higher degree dependent 
on AR than Akt activity. In contrast, in AI cells, the translocation of 
-catenin depended mainly on Akt activity. Cells supplemented 
with DHT and additionally treated with siRNA specific for Akt 
increased proliferation only in case of AS LNCaP line. These re-
sults implicate both genes, AR and Akt, in prostate cancer progres-
sion, as well as in the regulation of important targets like -catenin. 
Simultaneous silencing of AR and Akt resulted in inhibition of both 
Akt and -catenin expression more in AS than AI cells.  
-catenin Knockdown 
-catenin knockdown caused significant inhibition of prolifera-
tion in all studied prostate cell line in both time and dose-dependent 
fashion and was sufficient to down-regulate the expression of cyclin 
 
Fig. (8). Invasive potential of LNCaP, PC-3 and DU145 prostate cancer cells treated with siRNAs specific for AR, Akt and -catenin. A. quantitative real-time 
PCR analysis of MMP-9 expression. Gene expression is presented as fold increase in 2- CT. B. Cell photographs that illustrate differences in the number of 
migrating cells - cell invasion assay through Matrigel coated Boyden chamber. Data were obtained from four experiments. 
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D1, c-Myc and to increase p21Cip-1 in all cell lines, but the greatest 
effect was again observed in LNCaP cell line. Similarly, the de-
crease in cell migration was observed in all lines when either 
siRNA specific for AR+, siRNA specific for Akt or siRNA specific 
for -catenin were used. Li Xin [49] using cell-culture models has 
generated alternative views about the potential crosstalk between 
Akt and AR signaling by using reporter assays that measure AR 
transcriptional activity. They demonstrated a direct synergy be-
tween Akt and AR signaling that can transform prostatic epithelium 
into AI, but AR-dependent, carcinoma. Somewhat different cell 
response seem to depend on the presence of AR in LNCaP cells that 
expressed AR, DU145 with membrane AR [50] and PC-3 with no 
receptor.  
CONCLUSION 
Replacement of AR function by Akt in -catenin signaling may 
directly contribute to cancer progression in the case of the loss of 
androgen sensitivity/dependence. Using the inducible system of Akt 
activation, we demonstrated that active Akt plays a functional role 
in AI progression of prostate cancer. 
Akt signal transduction seems to be linked to AR modulation of 
basic cellular properties through as yet not fully understood mecha-
nism(s). Our results may provide a novel target of nuclear receptor 
modulators and indicate their potential as therapeutic targets in the 
treatment of prostate cancer.  
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ABBREVIATIONS 
AS = Androgen-Sensitive 
AI = Androgen-Insensitive 
AR = Androgen Receptor 
BPH-K = Primary Benign Prostate Hyperplasia Cells 
CA-K = Primary Prostate Cancer Cells 
DHT = Dihydrotestosterone 
MMPs = Metalloproteinases 
PPAR  = Peroxisome Proliferator-Activated Receptor Gamma 
PSA = Prostate-Specific Antigen 
SF = Steroid Free 
T = Testosterone 
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